- Exploring efficiencies from eTMF with Cancer Research UK
- GSK’s Zejula meets primary goal in Phase III ovarian cancer trial
- Trials data suggests Cosentyx from Novartis will change psoriasis market
- Eligibility criteria for clinical trials report challenges in representing LN patients
- Celltrion implements Veeva Vault eTMF to improve visibility into clinical trial activities
United Therapeutics’ Tyvaso meets goals in PH-ILD patients
United Therapeutics has reported that the Tyvaso (treprostinil) inhalation solution met all primary and secondary endpoints in the Phase III INCREASE trial involving patients with pulmonary hypertension caused by interstitial lung disease (PH-ILD).
Bristol-Myers initiates new cohort in Phase I/II trial of BMS-986249
Bristol-Myers Squibb (BMS) has launched an expanded Phase II cohort in the ongoing Phase I/IIa clinical trial of CytomX Therapeutics’ anti-CTLA-4 Probody candidate, BMS-986249.
Sojournix starts clinical trial of SJX-653 for menopausal hot flashes
Clinical-stage biopharmaceutical firm Sojournix has started a Phase II trial to evaluate the efficacy of SJX-653, a once-daily regimen for moderate to severe vasomotor symptoms (VMS), hot flashes, and night sweats associated with the menopause.
ReNeuron’s hRPC stem cell therapy yields positive results
ReNeuron Group has reported positive long-term efficacy data from the ongoing Phase I/II clinical trial of human retinal progenitor cell (hRPC) stem cell therapy in patients with retinitis pigmentosa (RP).
Adrenomed reports positive data of adrecizumab in septic shock
German biopharmaceutical firm Adrenomed has reported positive results from the proof-of-concept Phase II AdrenOSS-2 clinical trial of adrecizumab in patients suffering from early septic shock.
CytoDyn gets IRB approval for leronlimab’s Phase II basket trial
CytoDyn has received approved from the Institutional Review Board (IRB) to conduct its Phase II basket trial of leronlimab in patients with various solid tumour types.
IQVIA unveils new global site network to increase trial opportunities
IQVIA, a life sciences technology solutions provider, has launched a technology-based global site network that opens opportunities for more clinical trials at experienced clinical and research sites.
Cyclo Therapeutics concludes enrolment in Phase I/II NPC trial
Cyclo Therapeutics has completed patient enrolment in the Phase I/II clinical trial of intravenous Trappsol Cyclo in patients with Niemann-Pick Disease Type C1 (NPC1).
VBL Therapeutics initiates VB-111’s trial in colorectal cancer
VBL Therapeutics has initiated a Phase II clinical trial of a VB-111 and Opdivo (nivolumab) combination to treat patients with metastatic colorectal cancer (CRC).
Covid-19: First coronavirus vaccine trial submission expected in April
The earliest vaccine for the novel coronavirus in China will be submitted for clinical trials around late April, said China’s Vice Minister of Science and Technology Xu Nanping at a press conference.